Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Why This Matters I don't see an article…
Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru
A Phase I trial demonstrates that CBD powder formulation pharmacokinetics match oil-based products in healthy adults. The study reveals formulation-dependent food effects on absorption. While bioequivalence is established, clinical advantages remain…
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyMental Health Clinical Summary The Drug Enforcement…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Why This Matters I need the article summary to…
Cannabidiol inhibits phenytoin clearance and can result in clinical changes: Two cases.
Cannabidiol has well described drug interactions including inhibition of clobazam metabolism. Phenytoin is known to induce metabolism of cannabidiol. Cannabi...
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Why This Matters I don't see an article…